Fisher & Paykel Healthcare has reported a strong result driven by growing use of its products outside of intensive care, such as oxygen and humidity therapy, and the ability of the company’s Optiflow system to reduce the need for invasive therapies. Revenue rose 21% to NZ$816m for the year to 31 March compared to the prior comparable period.
Great result with expanding margin
Increased R&D spend
Premium to ResMed too high; Sell